financetom
Business
financetom
/
Business
/
Quantumscape Insider Sold Shares Worth $1,219,532, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Quantumscape Insider Sold Shares Worth $1,219,532, According to a Recent SEC Filing
Jul 12, 2024 2:24 PM

05:10 PM EDT, 07/12/2024 (MT Newswires) -- Mohit Singh, Chief Development Officer, on July 11, 2024, sold 173,224 shares in Quantumscape ( QS ) for $1,219,532. Following the Form 4 filing with the SEC, Singh has control over a total of 1,196,905 shares of the company, with 1,196,905 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1811414/000141588924019527/xslF345X03/form4-07122024_050702.xml

Price: 8.31, Change: +0.06, Percent Change: +0.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Invesco, CI Global Asset Management Complete Deal for Canadian Fund Business
Invesco, CI Global Asset Management Complete Deal for Canadian Fund Business
Jun 1, 2026
08:25 AM EDT, 06/01/2026 (MT Newswires) -- Invesco ( IVZ ) and CI Global Asset Management said Monday they have completed the transfer of management agreements for Invesco's ( IVZ ) Canadian fund business, covering about 27 billion Canadian dollars ($19.52 billion) in assets under management. The companies also said they formed a long-term partnership under which Invesco ( IVZ...
GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint
GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint
Jun 1, 2026
08:26 AM EDT, 06/01/2026 (MT Newswires) -- GRAIL's (GRAL) stock fell 11% in Monday's premarket session after the company said over the weekend that the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint. The NHS-Galleri trial evaluated a primary endpoint of Stage III and IV diagnoses in a group of 12 cancers. The company said...
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Jun 1, 2026
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity — — Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential Approval — — On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026...
Perpetua Resources Advances Stibnite Project in Idaho After Favorable Court Ruling
Perpetua Resources Advances Stibnite Project in Idaho After Favorable Court Ruling
Jun 1, 2026
08:28 AM EDT, 06/01/2026 (MT Newswires) -- Perpetua Resources ( PPTA ) continues to advance the Stibnite gold-antimony project in Idaho following a court decision denying a request to block development, the company said Monday. The U.S. District Court of Idaho denied on Friday a motion for a preliminary injunction filed by special interest groups in 2025. The court found...
Copyright 2023-2026 - www.financetom.com All Rights Reserved